Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. - Test2 - elhamkhani - TriplyDB

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

http://www.wikidata.org/entity/Q36406259

about

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment Efavirenz and the CNS: what we already know and questions that need to be answered Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.Importance of Drug Pharmacokinetics at the Site of Action Neurological and psychiatric adverse effects of antiretroviral drugs.Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum.Brain alterations within the first 100 days of HIV infection.Controversies in HIV-associated neurocognitive disorders Cortical neurons are a prominent source of the proinflammatory cytokine osteopontin in HIV-associated neurocognitive disorders Understanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection.Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.HIV and neurocognitive dysfunction.Neuronal toxicity of efavirenz: a systematic review.Animal models for depression associated with HIV-1 infection.HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Treating HIV Infection in the Central Nervous System.Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.Does efavirenz replacement improve neurological function in treated HIV infection?Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial.Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons.Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

P2860

Q26766448-EB40C149-4D1C-4197-8B20-A38525705015 Q28085028-E3F95CF7-F7CE-442E-A08C-D44B909D2969 Q30834094-A5F09629-4242-4ADE-BA40-21419EDFCE04 Q33648045-CCEBA869-69D1-40D0-A36A-47C658DFF9A8 Q34039419-13707DC6-2B4F-40A7-91F2-FBDBD4AE35C8 Q34389419-250ED9F6-8574-42E8-A4A0-D433715E34A3 Q34994446-8CB0F706-C01A-4FEF-AB5E-4CBC452AD619 Q35037015-5EA2D3E6-542D-4247-8A70-8EF5A0C7A313 Q35214668-E6D06336-78BC-41EB-A475-573AAF99970D Q35264787-D8558C2C-A78B-494C-BF4B-43C3386EAD03 Q36330202-5A4A0AEB-73B9-4CEF-8B29-0E5597711254 Q36554279-59AA3158-7A72-46BA-9F39-B4FE5C71D3DC Q36573340-DD4C1255-D31C-49BC-9C9C-1CCB9D77E984 Q36664960-46365675-5D81-4E1D-A4AE-8CBEB403CBE8 Q37026878-2224B210-D7DF-4EAF-AAA5-F26778CB789C Q37263885-7C2FF86F-19B4-4D50-9074-263B4A913035 Q37635032-D26155B7-F3A0-4209-A2F0-E666715F51A4 Q38122104-81D6A06C-8C72-429C-B9C4-771D1875E5D8 Q38124394-3462D194-603B-44B7-B961-9FF38005EE80 Q38171363-3FADC01D-9D42-49FA-B994-D7BD7BDDF26E Q38444808-8C91CB31-9506-4048-B5CD-F5DE780AABC7 Q38645161-C8F09C22-9595-449C-A9FD-2FF68CB79611 Q38755666-F0EC2289-4287-48BF-A470-F779B99AE7D2 Q38882614-26CC941B-1D80-487E-9127-F7F6724FF7C2 Q38921093-AE142FF6-C5F4-4808-938C-0D156A66B99D Q38976612-F1AE7A44-036F-4CF8-8001-3B3600844420 Q38987587-B82C790C-0293-4788-8AF1-1328C81B13B2 Q39077816-7CBC37EC-DD46-4289-8180-48CA71167070 Q39304616-8472353F-AAEB-42AB-8572-399C0D6032D7 Q39344476-94A80E03-1A1A-4087-879F-38A03629BA0A Q39364925-7346ED0D-5D7C-4AA0-A4D4-E014EE13563B Q40051820-E7C505F9-2534-4E03-AB9D-CD8142A13DE3 Q40129359-75677850-C3DF-412B-A868-85C0AFB57299 Q40531475-2E42320F-27A5-4AD1-8821-F76C9B241D45 Q40694902-73F32436-C85F-49D4-A6CA-29E54FA65FCF Q41208022-807299CC-155B-42BA-8BB0-6793B623567E Q41602074-1E956221-0331-4F23-BB40-AD089B99C9EB Q41663896-FBEF8968-27D0-46AD-82FC-738DEE6B954B Q42069973-528D7BF4-7BEE-41AC-B927-75E5F29312D8 Q42203691-0B0B99AA-7960-4188-A5C2-B31398C45F75

P2860

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

http://www.wikidata.org/entity/Q36406259

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@ast

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@en

type

label

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@ast

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@en

prefLabel

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@ast

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@en

P1433

Q36406259-D82BA303-FCFB-4AFC-88A7-D03921FE2C13

P1476

Q36406259-4A5141A8-02FE-488C-86A7-5787457D0D47

P2093

Q36406259-4151D3A5-1F30-4703-8643-B948F8952479

Q36406259-4E94183F-2EA3-499E-9EAE-9F5B64328D9A

Q36406259-8ECCBE8C-13CE-4AC2-84A1-92A7350AFEE7

Q36406259-D75FA16A-D0EC-4CDD-B37A-20E4B498B11B

Q36406259-E5E2919C-39B0-4E9A-8C66-CD1AB6350E68

Q36406259-FB4C7D0E-1C35-4D3E-B22A-9CA8D51C7288

P2860

Q36406259-07BB2107-6BF5-45A4-97B3-5FA685901BC6

Q36406259-0A188CFE-1F0F-4B1F-B6D4-F00E1F2AD2DF

Q36406259-0B054F3A-7DDE-460C-B5C6-216F8E10B54B

Q36406259-0E5600F5-CCFD-491D-A80C-FF3D346C56A4

Q36406259-0E9BFD47-5453-44FF-9616-01B4D6068F14

Q36406259-1867642F-AC4D-499D-93F7-F4DB8E458AA4

Q36406259-195F38D6-06B7-4433-9865-D7CF64BAE00C

Q36406259-1D2A3FBC-5420-4D0F-A37E-06B7C2B4CDD7

Q36406259-21746DD6-7CAF-4887-90E9-5C5D6870815A

Q36406259-2620DCD6-EBA9-4B54-86D6-E07528ED7217

P304

Q36406259-9B1B5779-3337-4F07-BE56-8500603CCCE9

P31

Q36406259-F3133458-9A4E-4709-92DF-773D405CAD36

P356

Q36406259-715B5226-99EC-4637-BAF0-60F11647E9C5

P407

Q36406259-EB94409E-07E0-476E-8B2D-903F5C5E51C9

P433

Q36406259-3162FEF1-A79F-4F3E-8FCE-43CAE12173D2

P478

Q36406259-747416A9-19FE-4E69-9660-DAB47F427E55

P50

Q36406259-302577A6-052F-4C64-8574-14E93EC41D0D

P577

Q36406259-89B160AC-95D4-40E6-82A3-1984E0905253

P5875

Q36406259-75E067BA-F770-4590-8CD8-380E7147836E

P698

Q36406259-685FB820-CB4B-4919-8A2F-4A5B07A400F3

P932

Q36406259-88CB12C5-D4C3-493F-B157-AB0B3E855AD1

P356

JPET.112.195701

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

@en

P2093

Daniel Pomerantz

http://www.w3.org/2001/XMLSchema#string

Justin C McArthur

http://www.w3.org/2001/XMLSchema#string

Lindsay B Avery

http://www.w3.org/2001/XMLSchema#string

Luis B Tovar-y-Romo

http://www.w3.org/2001/XMLSchema#string

Namandjé N Bumpus

http://www.w3.org/2001/XMLSchema#string

Norman J Haughey

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors

Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Pathogenesis of HIV in the central nervous system

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

P304

696-703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.112.195701

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230864862

http://www.w3.org/2001/XMLSchema#string

P698

22984227

http://www.w3.org/2001/XMLSchema#string

P932

3500535

http://www.w3.org/2001/XMLSchema#string